GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Shares Outstanding (EOP)

APLMW (Apollomics) Shares Outstanding (EOP) : 89.48 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Apollomics's shares outstanding for the quarter that ended in Jun. 2024 was 89.48 Mil.

Apollomics's quarterly shares outstanding stayed the same from Dec. 2023 (89.48 Mil) to Jun. 2024 (89.48 Mil).

Apollomics's annual shares outstanding stayed the same from Dec. 2022 (86.80 Mil) to Dec. 2023 (86.80 Mil).


Apollomics Shares Outstanding (EOP) Historical Data

The historical data trend for Apollomics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Shares Outstanding (EOP) Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
86.80 86.80 86.80 86.80

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial 86.80 86.80 89.48 89.48 89.48

Competitive Comparison of Apollomics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Apollomics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollomics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Apollomics's Shares Outstanding (EOP) falls into.



Apollomics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Apollomics  (NAS:APLMW) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Apollomics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Apollomics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollomics Business Description

Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.